- Home
- RDFN vs AGIO Comparison
RDFN vs AGIO Comparison
Compare RDFN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- AGIO
- Stock Information
- Founded
- RDFN 2002
- AGIO 2007
- Country
- RDFN United States
- AGIO United States
- Employees
- RDFN N/A
- AGIO N/A
- Industry
- RDFN Real Estate
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- AGIO Health Care
- Exchange
- RDFN Nasdaq
- AGIO Nasdaq
- Market Cap
- RDFN 1.2B
- AGIO 1.4B
- IPO Year
- RDFN 2017
- AGIO 2013
- Fundamental
- Price
- RDFN $9.81
- AGIO $32.66
- Analyst Decision
- RDFN Hold
- AGIO Buy
- Analyst Count
- RDFN 11
- AGIO 8
- Target Price
- RDFN $10.85
- AGIO $56.00
- AVG Volume (30 Days)
- RDFN 7.4M
- AGIO 550.4K
- Earning Date
- RDFN 05-06-2025
- AGIO 05-01-2025
- Dividend Yield
- RDFN N/A
- AGIO N/A
- EPS Growth
- RDFN N/A
- AGIO N/A
- EPS
- RDFN N/A
- AGIO 11.45
- Revenue
- RDFN $1,038,527,000.00
- AGIO $37,035,000.00
- Revenue This Year
- RDFN $0.10
- AGIO $27.43
- Revenue Next Year
- RDFN $2.78
- AGIO $189.81
- P/E Ratio
- RDFN N/A
- AGIO $2.80
- Revenue Growth
- RDFN 5.11
- AGIO 25.96
- 52 Week Low
- RDFN $5.49
- AGIO $23.42
- 52 Week High
- RDFN $15.29
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- RDFN 48.53
- AGIO 69.57
- Support Level
- RDFN $9.41
- AGIO $30.38
- Resistance Level
- RDFN $10.41
- AGIO $30.45
- Average True Range (ATR)
- RDFN 0.47
- AGIO 1.15
- MACD
- RDFN -0.02
- AGIO 0.41
- Stochastic Oscillator
- RDFN 33.50
- AGIO 90.61
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments real estate services, rentals, mortgage, title, and monetization. The company generates the majority of its revenue from Real estate services.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.